Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $79.97 SGD
Change Today 0.00 / 0.00%
Volume 0.0
As of 5:30 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-reg (LONZ) Snapshot

Open
--
Previous Close
$79.97
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
52.9M
EX-Date
04/9/15
P/E TM
--
Dividend
$2.43
Dividend Yield
4.35%
Current Stock Chart for LONZA GROUP AG-REG (LONZ)

Related News

No related news articles were found.

lonza group ag-reg (LONZ) Related Businessweek News

View More BusinessWeek News

lonza group ag-reg (LONZ) Details

Lonza Group Ltd. supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Specialty Ingredients and Pharma&Biotech. The Specialty Ingredients segment offers consumer care products comprising actives for antidandruff shampoos, and natural and organic cosmetic ingredients; vitamin B compounds; and microbial control solutions, including disinfectants and sanitizers that protect from dangerous and unwanted microbes. This segment also provides custom agricultural manufacturing services to enhance crop yields and food quality; industrial Solutions, including preservatives and biocide blends; products and services that enhance the quality of wood; and sanitizers and other treatment chemicals for pools, spas, water parks, as well as in the treatment of surface waters for drinking, agriculture, irrigation, food processing, and industrial applications. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients (APIs) for drug companies; microbial parenteral API, including antibody fragments, vaccines, cytokines, plasmid DNA, fusion proteins, and PEGylated products; and chemical custom services, such as chemically derived active ingredients, peptide syntheses, antibody drug conjugates, cytotoxic, and small organic molecules. It also offers cell culture, transfection, and molecular biology tools for life-science research; media used in the production of therapeutics; endotoxin detection assays; and products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer, and other disease research areas. This segment serves customers in academic and government institutions, and in biotech and pharmaceutical organizations. Lonza Group Ltd. was founded in 1897 and is headquartered in Basel, Switzerland.

9,809 Employees
Last Reported Date: 02/26/15
Founded in 1897

lonza group ag-reg (LONZ) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.1.3M
Compensation as of Fiscal Year 2014.

lonza group ag-reg (LONZ) Key Developments

Lonza Group Ltd Signs New Long-Term Product Supply Agreement with Alexion

Lonza Group Ltd. announced the signing of a new long-term product supply agreement with Alexion. Under the agreement Lonza will construct and launch a new suite dedicated to Alexion manufacturing. Lonza will own and operate the suite as part of its Portsmouth, NH (USA) site. This contract is an expansion of an existing manufacturing agreement. This agreement will supplement existing production of Alexion products at multiple Lonza facilities. The expansion of the existing site in Portsmouth, near Boston, MA (USA), will provide valued customers increased access to Lonza's proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service. Lonza has more than two decades of worldwide manufacturing experience with mammalian biotherapeutics.

Lonza Group Releases the QC Insider Toolbox

Lonza Group released the QC Insider Toolbox, a new internet portal to provide online support for the bacterial endotoxins test (BET). It offers comprehensive support tools, a wide range of training resources and a library of information that can be accessed at any time and from anywhere with internet access, to guide QC professionals through the QC process and help lead to success in endotoxin testing. The QC Insider Toolbox is organized into three areas - QC Insider Support, QC Insider Training and QC Insider Library - so that users can easily navigate directly to the resources they need. The QC Insider Support offers one-on-one guidance and detailed information about software support, recertification and testing services, reader installation and maintenance, and workflow optimization. The QC Insider Training contains self-directed training resources that will help users to increase their endotoxin testing expertise, including a series of how-to videos that demonstrate different assay procedures.

Lonza Group Ltd. to Expand Viral Therapy Business with Planned Construction of New Facility in Houston, TX

Lonza Group Ltd. announced the planned expansion of its viral gene therapy business. Lonza plans to construct a new 100,000 square foot facility for viral and immunotherapy development and manufacturing in the Houston, TX (USA) area, complete with a fully segregated fill/finish suite. This new facility will more than double Lonza's capacity for the production of viral gene and virally modified therapeutics. The multi-purpose facility is expected to come on-line in the first half of 2017 and will include eight independent cGMP modular cleanrooms for 2,000 L-scale production in single-use bioreactors. Grade-B cleanrooms will also be constructed to continue the manufacture of EMA-regulated cell therapy products. The site master plan includes expanded process development and quality-control areas, shell space for future additional cleanrooms, and land for further potential expansions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LONZ:SP $79.97 SGD 0.00

LONZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ashland Inc $121.91 USD -0.75
Clariant AG SFr.19.18 CHF -0.05
Croda International PLC 2,749 GBp -19.00
PerkinElmer Inc $52.24 USD -0.25
Wacker Chemie AG €94.72 EUR +0.232
View Industry Companies
 

Industry Analysis

LONZ

Industry Average

Valuation LONZ Industry Range
Price/Earnings 28.8x
Price/Sales 1.9x
Price/Book 3.2x
Price/Cash Flow 29.2x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-REG, please visit www.lonza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.